Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by stanleyon Jan 23, 2012 11:41pm

289 Views

Post# 19440104

RE: Brigus - Revisit Risk Reward Warnings

Terry:

Looking in the SI Link, reference is made to dilution and the size of some of the production equipment. RA mentioned that the reduction of (UG) dilution could be a combination of mining method change (longhole) and "re-tooling" of primary face equipment spread. Yet another transition to achieve de-risking of UG production.

This was a problem even with CMD in the Exall/Glimmer days. Jung Choi's shoes will be a huge one to fill when it comes to "planning between the cage to the face".

BWDIK? Drill bit versus jumbo steel, which one is going to win the day?

GLTAL-GLAP

Cheers

Stanley

Bullboard Posts

How one company is disrupting PoC testing